SYK and B-cell chronic lymphocytic leukemia: Other kinase inhibitors in clinical development for CLL include the PI3K inhibitors TGR-1202 and IPI-145 [53, 54], the BTK inhibitors CC-292 and ONO-4059 [55, 56], the SYK inhibitor GS-9973 [57], and the multikinase inhibitor dasatinib [58].